Interesting novel developments are clinical trials with MC4R-agonists in patients with leptin-melanocortin pathway deficiencies, e.g. POMC and LEPR deficiency, [44] and glucagon-like peptide 1 (GLP-1) agonists for adolescents with obesity. This evidence concerns the gene LEP and obesity due to leptin receptor gene deficiency.